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Abstract 
 
Choroid plexus tumours (CPTs) account for 2-5% of brain tumours in children.  They 
can spread along the neuraxis and can recur after treatment. Little is known about 
the molecular mechanisms underlying their formation and only few high fidelity 
mouse models of p53-deficient malignant CPTs are available.  
We show here that c-MYC overexpression in the choroid plexus epithelium induces 
T-cell inflammation-dependent choroid plexus papillomas in a mouse model. We 
demonstrate that c-MYC is expressed in a substantial proportion of human choroid 
plexus tumours and that this subgroup of tumours is characterised by an 
inflammatory transcriptome and significant inflammatory infiltrates. In compound 
mutant mice, overexpression of c-MYC in an immunodeficient background led to a 
decreased incidence of CPP and reduced tumour bulk. Finally, reduced tumour size 
was also observed upon T-cell depletion in CPP-bearing mice. Our data raise the 
possibility that benign choroid plexus tumours expressing c-MYC could be amenable 
to medical therapy with anti-inflammatory drugs.  
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Introduction 
Choroid plexus tumours (CPT) are intracranial neoplasms derived from the choroid 
plexus epithelium. They predominantly occur in children and account for 2-5% of all 
paediatric brain tumours, with relatively higher incidence in infants [1]. They mainly 
occur in the ventricles and mostly present with severe hydrocephalus. They may 
spread along the neuraxis and can recur after treatment. Histologically CPTs are 
classified into three categories - Choroid Plexus Papilloma (CPP, benign, World 
Health Organisation [WHO] grade I), Atypical Choroid Plexus Papilloma (ACPP, 
intermediate, WHO grade II) and Choroid Plexus Carcinoma (CPC, malignant, WHO 
grade III) [2]. CPC is known to be associated with younger age at diagnosis as 
compared to CPP [3]. 
Limited literature is available on the molecular mechanisms mediating the biology of 
these tumours. Merino et al. demonstrated that CPPs and ACPPs are molecularly 
distinct from CPCs at the genetic, epigenetic and expression level but molecular 
similarities suggest CPPs and ACPPs are a single entity [4]. In keeping with this 
interpretation another study showed that CPP and ACPP have similar cytogenetic 
features and that ACPP represent an immature variant CPP characterised by 
increased proliferative activity, whereas CPCs represent a genetically distinct group 
[5]. Tumour aggressiveness and poorer survival outcome in CPTs is associated with 
a greater number of copies of mutated TP53 [4, 6] and CPCs are also found in 
patients with Li-Fraumeni syndrome (germline mutation of TP53) [7] . Methylation 
profiling applied to CPTs led to the identification of 3 distinct subgroups with clinical 
relevance and confirmed that CPCs cluster separately from the majority of CPPs and 
ACPPs [2]. 
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Current management for choroid plexus tumours includes initial surgery with an aim 
to achieve gross total resection (GTR) which is associated with decreased risk of 
recurrence. Achieving GTR can be challenging (achieved in only approximately 63-
70% of CPTs) [8] and, as for all neurosurgical procedures, can be associated with 
postoperative co-morbidities such as visual changes (up to 16%) and seizures (up to 
13%) [1]. CPCs have a 20 fold higher risk of metastasis and local recurrence as 
compared to CPP [7]. Initial resection is followed in these cases by adjuvant therapy 
(radiotherapy and/or chemotherapy). Currently there are no disease-specific 
chemotherapeutic agents available. Indeed identifying druggable molecular 
aberrations for these tumours has been challenging, possibly because of their rarity 
and paucity of faithful pre-clinical experimental models. In particular, mouse models 
of CPPs are lacking and high fidelity models only exist for CPCs occurring in a Tp53-
deficient background [9, 10].   
 
The MYC family members, c-MYC, N-MYC and L-MYC, are well characterised 
regulators of cellular processes such as proliferation, apoptosis and cellular 
metabolism [11, 12]. Their essential role in embryonic stem (ES) cells and in early 
embryonic mouse development has long been known [13]. The key role of c-MYC in 
stem cell biology has been strengthened by the observation that its expression 
together with OCT4, SOX2 and KLF4 is sufficient to revert terminally differentiated 
fibroblasts into a pluripotent embryonic stem cell-like state [14]. c-MYC is also one of 
the first proto-oncogenes identified, it is overexpressed in a large number of tumours 
and its active role in oncogenic transformation of normal cells is well documented 
[15]. In brain tumourigenesis, deregulation of the expression of c-MYC has been 
shown to be functionally relevant for medulloblastoma and glioblastoma, the most 
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common intrinsic brain tumours in children and adult respectively (reviewed in [16]). 
MYC genes, most commonly c-MYC and MYCN, are frequently amplified in 
medulloblastoma [17] and are associated with a poor prognosis [18] and/or tumour 
recurrence [19]. In mouse models, inactivation of Tp53 and Pten in adult NSPCs 
induces high grade glial tumours through increased cellular c-Myc activity which 
leads to impaired differentiation, enhanced self-renewal capacity of NSPCs and 
tumour-initiating cells (TIC) as well as maintenance of TIC tumourigenic potential 
[20]. Moreover, human glioblastoma initiating cells preferentially express c-MYC and 
depend on its activity for self-renewal and tumour growth [21] and recently a novel 
MYC-mediated metabolic reprogramming has been described in these cells [22].  
 
Here, we set out to analyse the impact of genetically engineered c-MYC 
overexpression in NSPCs on brain tumourigenesis in the mouse. 
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Results 
Generation of a mouse line which overexpresses c-MYC in a spatiotemporally 
regulated manner. 
The Gateway Entry system [23] was chosen to guarantee controlled and efficient 
monosite insertion of the human c-MYC construct into the ubiquitously expressed 
ROSA26 locus [23] (Fig.S1A). This approach was used to ensure the overexpression 
achieved would be low level, thus mimicking the degree of c-MYC overexpression 
observed in human malignancies (reviewed in [24]). Genotyping of the chimeras was 
performed using primers to detect the eGFP reporter gene (Fig.S1B), germline 
transmission and line establishment was achieved (STOPFloxc-MYC). Expression of 
human c-MYC was confirmed by western blot analysis in NSPCs isolated from the 
postnatal transgenic mouse SVZ and treated with A-Cre (Fig.S1C). Concomitant 
expression of GFP was seen in these cultures (Fig.S1D), as expected because of 
the IRES-eGFP sequence contained in the targeting construct (Fig.S1A).  
The mouse line generated here allows for low level c-MYC overexpression in the 
desired cell population at the desired time.  
 
Choroid plexus tumours developed at high penetrance in NestinCre;STOPFlox-
c-MYC transgenic mice. 
To model c-MYC induced brain tumourigenesis, STOPFlox-c-MYC mice were 
crossed with NestinCre mice (Fig.1A), a Cre driver known to target NSPCs and the 
progeny derived thereof from E10.5 onwards [25]. The offspring were crossed 
between each other to obtain NestinCre;STOPFloxc-MYChet (heterozygous c-MYC 
allele), NestinCre;STOPFloxc-Mychom (homozygous c-MYC allele) and single 
Merve et al.  8 
 
transgenic littermates as controls. We included in the experimental setting both 
heterozygous and homozygous transgenic mice to also assess the impact of c-MYC 
dosage on NSPCs functional properties in vivo. 
 
51 double transgenic mice (43 NestinCre; STOPFloxc-MYChet and 8 NestinCre; 
STOPFloxc-MYChom) were generated and kept under tumour watch; mice were 
killed when symptomatic or at termination of the experiment (20 months).   
Post mortem examination of the brains of these animals revealed choroid plexus 
tumours (CPT) in a high proportion of the mutant mice (c-MYCOver CPT) (Fig 1B,C). 
Immunohistochemistry for GFP confirmed activation of the construct in the choroid 
plexus of 38/51 mutant mice with equal distribution between heterozygous and 
homozygous genotypes (Fig 1D). CPT were found in 32 of these mice (84.2% 
penetrance) (Fig 1C) and occurred in both genotypes (the penetrance in 
heterozygous and homozygous was 87.9% and 60% respectively; the difference was 
not statistically significant) (Table S1).Histologically the tumours showed papillary 
architecture with epithelial multilayering and focal solid pattern of growth, mild to 
moderate cellular and nuclear pleomorphism, in some cases with prominent nucleoli. 
Subarachnoidal spreading and/or brain invasion was noted in a proportion of the 
cases. Those tumours with mild cellular stratification, preserved papillary 
architecture, mild cellular and nuclear atypia and with mitoses of 2 or less/10 HPF 
were regarded as choroid plexus papilloma (CPP, Fig 1E & G). Those tumours with 
patchy solid growth, more pronounced (moderate) atypia with prominent nucleoli and 
presence of mitotic activity of 3 or more/10 HPF were classified as atypical choroid 
plexus papilloma (ACPP, Fig 1F & H). ACPPs had significantly higher Ki-67 
proliferation index as compared to CPP – mean values of 14.0 vs 0.55 Ki67+ 
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cells/HPF respectively (n=3, p=0.04, Fig 1 I-K). Of the 32 tumours, 26 (81.3%) were 
CPP (Fig.1C) and 6 (18.7%) were ACPP (Fig. 1C), 29 were in heterozygous and 3 
were in homozygous compound mutant. Of the 6 ACPPs, 2/3 were in homozygous 
compound mice and 4/29 in heterozygous compound mice. Six of the thirty two mice 
with CPT developed symptoms between 11 and 18 months. Severe hydrocephalus 
was detected in 6/32 (18.8%) mice with CPTs, among which 4 (66.6%) showed 
ACPP histology. The CPTs were marginally more frequently detected in the fourth 
ventricle (in 28 of 32, 87.5%) as compared to lateral ventricle (75%), whilst atypia 
was more common in the fourth ventricle (5 of 6, 83.3%). Only 1 of 32 tumours 
(CPP) showed dystrophic calcification. Severe pleomorphic features and necrosis 
were not seen.  A retrospective analysis showed that tumours developed as early as 
5 months of age. The tumour characteristics are summarised in Table S1.  
No CPT were detected in 34 control mice (STOPFloxc-MYC, single transgenic) and 
the choroid plexus of these mice were negative for GFP. No other brain tumours 
were detected in the double transgenic mice.  
 
c-MYC overexpression in the epithelial lining of the postnatal CP induces 
neoplastic transformation.  
Analysis of the Allen Brain Atlas spatial transcriptomic datasets revealed robust 
expression of c-Myc in the CP of adult mice, whilst no expression was noted at 
embryonic timepoints (Fig.S2A-F). Meta-analysis of human and murine expression 
datasets confirmed that both species expressed similar levels of c-MYC (Fig. S2H), 
there was good concordance of gene expression (Fig.S2I), the majority of expressed 
genes were shared (Fig.S2J) and these genes belong to key molecular pathways 
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(Fig.S2K), hence supporting further investigation of this model of c-MYC 
tumourigenesis. 
Firstly, we set out to define the biological history of these tumours. Histological 
analysis of NestinCre; STOPFloxc-MYC double transgenic brains at embryonic and 
postnatal timepoints (E12.5, E16.5, P7, P15, 3 months) showed no abnormalities at 
E12.5 and E16.5 and no expression of GFP (data not shown). The CP was slightly 
more bulky at P7 (Fig.2A,B), although no definite atypia was seen and a staining for 
GFP was negative (data not shown). Patchy hyperplasia with mild nuclear atypia 
was noted at P15 (Fig 2C,D), a timepoint where expression of GFP in the 
hyperplastic areas was noted (Fig 2E,F) in keeping with activation of the construct in 
the epithelial lining. Similar findings were found at 3 months (Fig 3G,H), when 
significantly increased proliferation was first noted (Fig 2I-K).  
Interestingly, at 5-6 months of age morphological abnormalities in keeping with CPP 
were detected in 3 of 6 (50%) compound mutant mice (2 het, 1 hom), with cellular 
stratification, multi-layering and mild nuclear atypia of the epithelium. CPP were 
detected in 3 of 4 mice (75%, 2 het 1 hom) at 9-12 months of age (Table S1). 
Increased proliferation was observed in compound mutant mice – 0.53 vs 0.16 
(p=0.034) and 0.65 vs 0.1 (p=0.005) - at 5-6 months and 9-12 months respectively 
(Fig 2K). There was no significant difference in apoptosis as assessed by 
immunohistochemistry for cCASP3, a central executor in the main apoptotic 
pathway, at all time points analysed (data not shown).       
The co-expression of CFP and transthyretin in scattered epithelial cells of the 
postnatal mouse CP in Nestin-CFP mice [26] suggested that our construct was 
expressed in the epithelial lining of the CP (Fig. S2G). To confirm that it was c-MYC 
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overexpression in the CP epithelium what led to tumour formation, we set up to 
isolate, culture and functionally analyse primary CP cells from newborn STOPFlox-c-
MYChom mice and confirmed in the first instance that they were composed of 
epithelial CP cells by means of immunostaining for transthyretin (over 95% of the cell 
population was TTR+, Fig.2L).  A-Cre infection induced recombination of the 
construct and its concomitant activation was confirmed by assessment of GFP 
expression in the culture (c-MYCOver CP) (Fig.2M). Increased proliferation, as 
assessed by Edu immunolabelling (Fig.2N,O-P) and decreased apoptosis, as 
determined by cCASP3 staining (Fig.2Q-S, n>3), was observed upon c-MYC 
overexpression. A soft agar colony formation assay confirmed that epithelial CP cells 
overexpressing c-MYC acquired anchorage independent growth (Fig.2T,U), 
providing evidence of cellular transformation in vitro [27]. 
In summary, these experiments show that low level overexpression of c-MYC in the 
CP epithelium induces CPP with high penetrance.  
 
c-MYC is expressed in a substantial proportion of human choroid plexus 
tumours.  
Next, we set out to interrogate a publicly available gene expression dataset 
[Affymetrix Human Exon 1.0 ST platform, GEO GSE60886] [4] of 40 human CPTs to 
assess whether expression of c-MYC would characterise a proportion of these 
tumours and whether genes could be identified linked to c-MYC expression. We 
show that c-MYC is expressed in a proportion of CPTs and we identify 356 genes of 
over 18,000 genes targeted by the core probes on the exon array, the expression of 
which was significantly correlated with c-MYC expression (absolute Pearson 
correlation coefficient r ≥ 0.5, p<0.01). Hierarchical clustering of the samples based 
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on the expression levels of these genes showed partition into high, medium and low 
c-MYC expressing tumours (Fig.3A). 
 
Next, we assembled an independent cohort of 42 CPTs comprising 24 CPPs, 12 
ACPPs and 6 CPC to validate c-MYC expression (Table S2). Histology was 
reviewed and both diagnosis and grading confirmed (Fig.3B-D). 
Immunohistochemistry was performed to determine c-MYC expression and tumours 
were classified as either positive or negative. While most of the positive tumours 
showed focal/patchy expression (Fig.3E), two of them showed diffuse expression 
(Fig 3F). A total of 18/42 (43%) tumour cases showed positive immunolabelling for c-
MYC, among which 4/6 (67%) CPC, 6/12 (50%) ACPP and 8/24 (33%) CPP were 
positive (Fig 3G). There was no significant correlation between c-MYC expression 
and tumour grading or between c-MYC expression and age of the patients (data not 
shown). Evidence of c-MYC amplification at the DNA level was not found in any of 
the tumour samples expressing c-MYC, as assessed by FISH (data not shown), in 
keeping with lack of significant correlation between c-MYC expression and gain of 
Chromosome 8 as found in the Merino et al. dataset. No correlation was found 
between TP53 staining and c-MYC expression (data not shown), a finding which was 
also in keeping with the results of our analysis of the Merino et al. dataset.  
These results show that a proportion of CPT expresses c-MYC in two large cohorts 
of these tumours.  
 
Deregulation of inflammatory pathways in c-MYC overexpressing CPT 
Next, we looked more closely at the list of genes significantly correlated with c-MYC 
expression in human CPT and noticed that 11 out of the top 20 positively correlated 
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genes were inflammation related, mostly chemokines and their receptors (Fig.S3A). 
Functional annotation clustering of all 356 genes using Ingenuity® Pathway Analysis 
confirmed that the majority of canonical pathways significantly enriched in CPT in 
this gene list were immune related (Fig S3B,C and D).  
To assess whether the transcriptional signature in our murine model would 
recapitulate the observation in human c-MYC+ CPT, we performed differential 
expression analysis between 3 murine CPT and 3 control CP samples. Significant 
overexpression of c-MYC was confirmed in the CPT samples (Fig. 4A) and 
expression of c-MYC targets, belonging to a cell-type independent c-MYC signature 
[28], was found enriched in CPT relative to control mice (Fig. S4A).  
245 genes were significantly deregulated (FDR < 0.05) in murine CPT and the 
enrichment of pathways such as Leucocyte extravasation signalling, 
Granulocyte/Agranulocyte adhesion and diapedesis, Tp53 signalling pathways, 
among others, was seen in CPT context (Fig. 4B).  
Next, we performed a correlation analysis (absolute Pearson coefficient r ≥ 0.5, p-
value < 0.05) and 2290 genes were retained, the expression of which significantly 
correlated with c-MYC expression in murine CPT samples. The corresponding 
heatmap shows a clear partition between control and CPT samples (Fig. 4C). Also, a 
similar pattern emerged from the expression of the murine orthologs of the 356 c-
MYC-correlated genes found in human CPTs (Fig. 4D), confirming activation of the 
MYC signalling cascade in human c-MYC+ tumours and murine CPT. 
To assess whether these transcriptomic data reflected a differential inflammatory cell 
recruitment to c-MYC expressing CPT, we stained our cohort of human CPT tumour 
samples for CD3 (T-lymphocyte marker) and CD68 (macrophage marker) and 
comparatively quantified the number of positive cells in c-MYC+ and c-MYC- 
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tumours. We show a significantly increased number of T-lymphocytes within the c-
MYC+ tumours as compared to c-MYC- tumours –12.28 vs 3.8 CD3+ cells/HPF 
(Fig.5A, p=0.046). Quantification of T-lymphocyte subtypes by CD4 and CD8 
immunostaining revealed that it was the CD4+ component which was responsible of 
the observed increase of T-lymphocytes - 9.49 vs 5.2 CD4+ cells/HPF between c-
MYC+ tumours as compared to c-MYC- tumours (Fig.5B, p=0.027). Whilst the 
number of CD3+ cells was higher than the one of the CD4+ cells, as predicted, in the 
c-MYC+ tumours -12.28 CD3+ cells and 9.49 CD4+ cells- this was not the case in c-
MYC- tumours -3.8 and 5.2- and the reason for this discrepancy is at present 
unclear. Nevertheless a convincing higher number of CD3+ and CD4+ cells were 
found in c-MYC+ tumours as compared to c-MYC- tumours, which is well in keeping 
with the results of the transcriptomic analysis.  
A significantly increased number of macrophages was also observed in c-MYC+ 
tumours as compared to c-MYC- tumours - 58.25 vs 26.87 CD68+ cells/HPF (Fig.5C, 
p=0.03). There was no significant difference in CD8+ subpopulation among these 
two cohorts (Fig S5A) and no significant difference in B-lymphocyte infiltrates, as 
assessed by CD20 immunostaining, was observed (Fig S5B) 
 
Comparative analysis of the murine CPT versus normal CP confirmed a significant 
number of T-lymphocytes and macrophage in the tumours – 4.61 vs 1.24 CD3+ 
cells/HPF for T-lymphocytes (Fig 5D, p=0.00075) and 3.44 vs 0.33 F4-80+ cells/HPF 
for macrophages (Fig.5E, p=0.011). Analysis of earlier time points in 
NestinCre;STOPFlox-c-MYC revealed no statistically significant increase in 
infiltrating T-lymphocyte or macrophage in the choroid plexus of double transgenic 
mice as compared to wild-type mice until 9 months (Fig.S5C,D).     
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These finding show a significant inflammatory component in the human CPT 
expressing c-MYC, which was recapitulated also in the murine model generated by 
genetically engineered c-MYC overexpression in the CP epithelium.  
 
Crossing onto a NOD-SCID background and CD3 depletion in vivo reduces 
tumour bulk in NestinCre; STOPFlox-c-MYC mice. 
To assess the functional role of the inflammatory infiltrates in the initiation of 
tumourigenesis in murine CPT, we crossed NestinCre; STOPFlox-c-MYC mice onto 
a NOD-SCID background. We show a significant reduction in tumour incidence in the 
triple compound mutant (NestinCre; STOPFlox-c-MYC;NOD-SCID) as compared to 
double compound mutant (NestinCre; STOPFlox-c-MYC) generated from the same 
crossing (50% vs 92.8%, p<0.05) (Fig.6A, n=14 for double transgenic and n=8 for 
triple transgenic). In addition, the size of the tumour, as assessed by Definiens digital 
tissue image analysis software on serial sections, was smaller in the triple mutant 
mice as compared to the double mutant mice (Fig.6B,C, n=6 for double transgenic 
and n=5 for triple transgenic cohorts).   
Next, we set out to systemically deplete T cells in tumour bearing NestinCre; 
STOPFloxc-MYC mice to assess the impact of inflammation on tumour growth in a 
setting that would more closely mimic a therapeutic approach. A T cell depletion 
strategy was chosen because of the increase in CD3+ T-lymphocyte in murine CPT 
and the enrichment for T-lymphocyte-regulatory pathways in the geneset significantly 
correlated with c-MYC expression in human CPT.  
 
Effective suppression of CD3+ cells in the blood and in the spleen of mice treated 
with anti-CD3 antibody was shown as compared to mice injected with isotype control 
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(Fig.6D-F). Further subtyping of the CD3+ cells revealed that the depletion strategy 
mainly impacted the CD4+ T cell fraction whilst no significant effect was seen on the 
CD8+ fraction (Fig.S6A-C). Double labelling also revealed that it was the CD4+ and 
FoxP3+ fraction of T-cells which were particularly impacted by the treatment 
(Fig.S6D). Significant reduction of the tumour area was found in the anti-CD3 
injected cohort (Fig.6G,H, n=9 for anti-CD3 treated cohort and n=8 for isotype control 
cohort) as assessed by Definiens digital tissue image analysis software on serial 
sections encompassing the entire tumour area. Immunohistochemical analysis 
confirmed reduction of CD3+ positive T cells (Fig.6I,J, n=9 for anti-CD3 treated 
cohort and n=8 for isotype control cohort). No significant impact of the CD3 depletion 
strategy was noted on macrophage infiltrates (Fig.6J).   
We conclude that T-lymphocyte depletion in murine c-MYC driven CPT has an anti-
tumourigenic effect.        
 
Discussion 
We show here that c-MYC overexpression in the choroid plexus epithelium induces 
inflammation-dependent choroid plexus papillomas in a mouse model. c-MYC is 
expressed in a proportion of human choroid plexus tumours and this subgroup of 
tumours is associated with an inflammatory transcriptome and significant 
inflammatory infiltrates.   
 
The expression of c-MYC in neural progenitor cells (NSPCs) was achieved via 
Nestin-driven Cre expression. The line is known to enable widespread recombination 
of LoxP flanked constructs in the developing CNS, including the CP as described in 
the original characterisation of the expression pattern of the line in a crossing with a 
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reporter mouse [25].  Nestin has been shown to be expressed in the roof plate, an 
organising centre from which CP epithelial cells originate [29]; however we do not 
find evidence of construct activation during embryonic development. CP epithelial 
cells have been shown to upregulate the expression of Nestin under specific 
conditions, such as the exposure to CSF obtained from patients with acute traumatic 
brain injuries [30]. In fact we found that activation of the construct in the CP occurred 
early postnatally, reflecting a physiological expression pattern for Nestin.  
 
CPTs developed with high penetrance (84.2%) in these mice from 5 months of age.  
The majority of the tumours observed fulfilled the WHO 2017 criteria for a diagnosis 
of CPP, however nearly a fifth of them displayed atypical features, in keeping with 
ACPP. Definite malignant features which would be required for the diagnosis of CPC 
were not found in any of the tumours examined. c-Myc overexpression in 
combination with Tp53 deficiency, has been shown to induce aggressive CPC at 
100% penetrance in less than 150 days in the mouse [10]. Alterations in cell cycle 
regulation and DNA damage responses were shown at transcriptome level raising 
the possibility that these molecular mechanisms could be pathogenetically relevant. 
Deregulation of mechanisms involved in DNA maintenance and repair had been 
previously linked to CPC pathogenesis (38% penetration in less than 220 days) in a 
mouse model where deletion of Tp53, Rb and Pten was achieved in newborn mice 
by electroporation of Cre Recombinase into the hindbrain CP epithelium at E12.5 [9]. 
Comparison of differentially expressed transcriptome signatures of both models 
revealed a 60% overlap with an enrichment of signalling pathways involved in cell 
proliferation and DNA damage responses [10], in keeping with the shared 
concomitant Tp53 deficiency.   
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We describe here the first mouse model of CPP/ACPP in a genetic background 
retaining expression of Tp53 (Fig.S4B). We show expression of c-MYC in a 
proportion of human CPTs in two large cohorts as well as a lack of association of c-
MYC expression and TP53 mutations/deficiency in both cohorts. Therefore, our 
model recapitulates the phenotype/genotype of a subgroup of benign human CPT. 
Overexpression of c-MYC alone in NSPCs was recently reported to induce CPCs at 
full penetrance at 8 weeks of age with tumours displaying a full blown malignant 
phenotype, including mitotic activity above 5/10HPF, severe nuclear pleomorphism 
and necrosis [31]; increased ribosome biogenesis was suggested as potential 
pathogenetic mechanism in these tumours [31]. We never observed CPCs in our 
compound mice, in keeping with previous reports in both mice [9, 10] and human [7] 
of TP53 deletion/inactivating mutations underlying the vast majority of CPC. It is 
conceivable that differences in expression levels of c-MYC as well the different Cre 
driver used could explain this difference, although it is unclear which human CPC, 
the Shannon et al. model would recapitulate.  
 
Increased proliferation and reduced apoptosis were observed in c-MYCOver CP cells 
and increased colony formation in the soft agar assay confirmed the transformation 
potential of the genetic modification introduced. These in vitro results were paralleled 
by modest increased proliferation in vivo, which was not counteracted by increased 
apoptosis both in vitro and in vivo. Overexpression of c-MYC led to the formation of 
CPT but it was not sufficient to elicit the formation of neural tumours, the latter 
finding confirming previous reports [32]. These results are in keeping with a model 
whereby increased expression levels of c-MYC elicit different biological outputs in a 
tissue-specific fashion and is in keeping with previous studies [33].  
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Interestingly, meta-analysis of a publicly available transcriptomic dataset of human 
CPTs [4] showed expression of c-MYC in a proportion of tumours. Expression of c-
MYC in human CPTs of all grades was confirmed in a large independent cohort of 
these tumours, which we assembled in the UK. We found that gene amplification at 
the DNA level was not the cause of c-MYC expression, a finding in agreement with 
an indirect oncogenic activation of c-MYC.  Deregulation of c-MYC expression is 
observed in more than half of human cancers and can be a consequence of gene 
amplification, chromosomal translocation, and/or protein stabilization [34]. Most 
frequently though, oncogenic activation of c-MYC is indirect, for example due to 
dysregulation of pathways physiologically regulating c-MYC (reviewed in [11]). In 
CNS tumours, c-MYC overexpression without underlying gene amplification is seen 
in glioblastoma [35] and in the WNT subgroup of medulloblastoma [36].  
 
The CP is functionally responsible for maintaining the blood-CSF barrier and 
contributes to mounting a cellular response to infection via production of cytokines 
and chemokines such as interleukins, TNF-α attracting inflammatory cells [reviewed 
in [37]. Perhaps unsurprisingly then, an inflammatory signature has been described 
in a proportion of benign CPT [38, 39]. We show here that it is linked to c-MYC 
expression.  
Interestingly, we found a highly significant correlation of the expression of 
inflammatory cytokines and their receptors with c-MYC expression in the Merino et 
al. transcriptomic dataset of human CPTs and in our mouse model. Importantly, the 
number of CD3+ T-lymphocytes (with predominantly CD4+ T-helper cell population) 
and CD68+ macrophages infiltrating the c-MYC+ CPTs of our cohort was higher as 
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compared to c-MYC- CPTs. Because inflammatory infiltrates with a similar cell 
composition were observed in our c-MYC-driven mouse model, we reasoned that the 
inflammatory component was likely induced by c-MYC. Because no inflammation 
was noted in other c-MYC-driven CPT models [10, 31], it is conceivable that lack of 
concomitant inactivation of Tp53 could contribute to this phenotype.  
Links between tumours and inflammation are well established, although the 
molecular mechanisms underpinning these links are not clearly understood and are 
very diverse in different tumour types (reviewed in [40]). Two main pathways define 
the tumour/inflammation connection- an extrinsic pathway, driven primarily by 
inflammatory conditions which increase oncogenic risk (such as inflammatory bowel 
disease causing bowel cancer); and an intrinsic pathway, driven by genetic 
alterations such as oncogenic mutation in RAS, c-MYC and RET causing activation 
of downstream inflammatory signalling (reviewed in [41]). c-MYC is overexpressed in 
many tumours, where its role in regulating cellular proliferation and survival is well 
known (reviewed in [42]). c-MYC function in remodelling the extracellular 
microenvironment via regulation of anti-tumour immunity has also been shown [43] 
and c-MYC-regulated inflammatory responses to tumourigenesis have been 
characterised [44, 45].  
The significantly lower incidence of CPP in an immunodeficient background (NOD-
SCID) together with the reduced tumour mass in those compound mutant mice 
developing tumours supports a pro-tumour role of the inflammation in our 
experimental setting. Reduction of the CPP tumour mass upon treatment with a T-
cells depletion therapy mainly impacting on the CD4+ fraction of T-cells and not 
impacting on the macrophages, confirmed the finding in a setting more closely 
mimicking a potential therapeutic approach. Whether the macrophage infiltration 
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observed could contribute to the phenotype in addition to the T-cell infiltration is at 
present unclear.  
 
A recent randomised, double-blind, placebo-controlled trial shows the impact of an 
anti-inflammatory therapy with canakinumab targeting the IL-1β innate immunity 
pathway on lung cancer incidence and mortality [46]. Our findings in benign 
CPP/ACPP provide the molecular foundation for further investigation of the potential 
role of anti-inflammatory drugs, in particular IL-1 receptor antagonists such as 
Anakinra (IL-1Ra) or Canakinumab (human monoclonal antibody specifically 
targeting IL-1b) in the treatment of c-MYC+ choroid plexus tumours and raise the 
possibility that the spectrum of tumours which may be responsive to anti-
inflammatory therapy could be broader than currently thought.  
 
Material and methods 
Generation of a c-MYC overexpressing mouse line 
The Gateway Entry system was chosen to guarantee controlled and efficient 
monosite insertion of the c-MYC construct into the ubiquitously expressed ROSA26 
locus [23]. The toxin-encoding ccdB gene was excised from the pENTR1A vector 
(Invitrogen) by BamH1/Xho1 restriction digest and a 1.5 kb cDNA construct of 
human c-MYC was inserted into these sites of the pENTR1A vector. BamH1/Xho1 
restriction digest showed correct insertion of the construct. Correct orientation of the 
insert was confirmed by DNA sequencing (data not shown). The c-MYC construct 
was subsequently inserted into a targeting vector via in vitro recombination. Since 
the c-MYC construct in the pENTR1A vector is flanked by specific lambda phage 
integrase recognition sites (attL), the c-MYC construct could be efficiently transferred 
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to a targeting vector carrying the corresponding heterotypic sites (attR). The 
targeting vector contains a 5’ homology region to the mouse ROSA26 genomic 
locus, a splice acceptor (SA) site, a PGK-neo-3x pA stop cassette flanked by loxP-
sites (LSL), the c-MYC construct, an IRES-eGFP reporter gene, a 3’ homology 
region to the mouse ROSA26 genomic sequence and a Diphteria Toxin A (DTA) 
selection cassette (Fig. S1A). It was electroporated into G4 F1 hybrid ES cells and 
screening for positive clones with correct insertion was performed by PCR using a 
forward primer in the genomic ROSA26 locus 5’ of the targeting vector and a reverse 
primer in the 5’ region of the targeting vector (Fig.S1A). Correctly targeted clones 
showed a 1.3 kb band as a result of the PCR screening. This was further validated 
by Southern Blot analysis (data not shown). Three of the positive ES cell clones 
(1B12, 2D4 and 2B8) were selected for injection into blastocysts from C57BL/6 mice 
to generate chimeric mice. This part of the procedure was performed by the London 
Research Institute Transgenic Service. Genotyping of the chimeras was performed 
using primers to detect the eGFP reporter gene. Germline transmission and line 
establishment was achieved for clone 1B12, from now on referred to as STOPFloxc-
MYC. 
 
Mouse strains, genotyping procedures and construct activation 
A NestinCre transgenic line [25] was used to activate c-MYC expression from the 
STOPFloxc-MYC construct and NODSCID mice were used to generate the triple 
compound mutant mice. Ear notches of transgenic mice were digested in lysis buffer 
(50 mM Tris, pH 8.0, 100 mM EDTA, 100 mM NaCl and 1% SDS) and Proteinase K 
(Biolabs) for three hours at 55o C. DNA was precipitated in isopropanol-2 (Fisher 
Scientific) and dissolved in TE buffer (10 mM Tris,1 mM EDTA, pH 8.0) for 30 
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minutes at 55o C. Genotypes of mice were determined by PCR, using published 
primer sequences [47-49]. All procedures had Home Office approval (Animals 
Scientific Procedures Act 1986, PPL 70/6452). 
 
Choroid plexus cultures 
CP tissue was dissected from brain ventricles of neonatal STOPFloxc-MYC mice 
aged 3-5 days postpartum. The tissue was washed with Hanks' Balanced Salt 
solution (HBSS, Sigma) and digested in pre-warmed and freshly prepared 
pronase/HBSS solution (2 mg/ml in HBSS and filtered through a 0.22 μm filter unit) 
at 37◦C for 5 min. The reaction was stopped by adding complete growth medium 
(Dulbecco’s modified Eagle’s medium nutrient mix F-12 supplemented with 10% fetal 
bovine serum, 50 U/ml penicillin, 50 μg/ml streptoMYCin, 2.5 μg/ml amphotericin). 
The digested tissue was collected by centrifugation at 1,000g for 2 min. The pellet 
was re-suspended in complete growth medium by gentle pipetting up and down (15–
20 times) to generate a suspension of single cells and cell aggregates. The CP cells 
were then counted and seeded on the culture plate for growing. Twenty µM of Ara-C 
was added into the cells overnight to inhibit the fibroblast cells proliferation. Medium 
was changed every two days until the cells reached confluence for passaging. After 
passaging, either Cre or GFP adenovirus was added to activate the construct. 
 
Patients and tumour samples 
Paraffin embedded tissue blocks or glass slides of CPT samples were obtained from 
Oxford University Hospitals NHS Trust, Nottingham University Hospitals NHS Trust, 
Imperial College Healthcare NHS Trust and University College London Hospitals 
NHS Trust under the UK Brain Archive Information Network (BRAIN UK) umbrella 
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(Approval no. 18/001 incorporating previous 13/003 and 15/007). Samples were also 
received from Children’s Cancer and Leukaemia Group (CCLG) University of 
Leicester (CCLG Biological Studies Steering Group Approval no. 2013 BS 03). 
Informed consent was obtained from all of the patients or parents/guardians in case 
of children. Ethical Approval from UK Research Ethics Committee was available 
under the BRAIN UK and CCLG umbrella. The tissue samples were received, stored 
and processed as per protocol.  
 
We studied 42 tumour samples from 40 patients (adults and children) including 
recurrence tumour samples from 2 of the adult patients (Table 2). Among the 
recurrences, histological grading remained the same in one, whereas there was 
histological progression in the other. Histopathological review was carried out by two 
board certified neuropathologists (AM and SM). Immunohistochemical analysis for 
INI1 (hHF5) was performed on all cases to exclude atypical teratoid/rhabdoid tumour 
(AT/RT) [50] and cases with INI1 mutation (negative staining) were excluded from 
the study.  
 
Immunohistochemistry and immunocytochemistry 
Formalin fixed paraffin embedded (FFPE) tissue sections of mouse brain and human 
CPT samples were used for immunohistochemistry. The mouse samples were 
processed at UCL IQ path laboratory and the human samples at the Histopathology 
Department, The Royal London Hospital, Great Ormond Street Hospital and UCL IQ 
path. Dewaxing, antigen retrieval and pre-treatment with appropriate serum was 
performed as per published protocols. The following primary antibodies were used 
for mouse tissue on automated Ventana Discovery XT platform: Monoclonal antibody 
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for the green fluorescent protein (GFP) from the jellyfish Aequorea Victoria (Abcam, 
ab290) 1:1500, CD3 (Leica/Novocastra, LN10) 1:100, F4-80 (Abcam, ab6640) 1:100, 
Ki-67 (Cell Signalling, 12202S) 1:100 and Caspase-3. (Cell Signalling, 9661L) 1:100. 
Anti-rabbit (Dako, E0353), anti-rat (Dako, E0468) and anti-mouse (Dako, E0354) 
secondary antibodies were used as required. For human CPTs the following primary 
antibodies were used on Launch 16000 Optimax autostainer: C-MYC (Abcam, 
ab32072) 1:50, CD3 (Leica, NCL-L-CD3-565) 1:50, CD4 (SP35, Roche), CD8 
(SP57, Roche), CD20 (L26, Roche) prediliuted, CD68 clone KP1 (Dako, M0814) 
1:150. P53 staining was performed using clone D07 (Ventana, 05278775001) 
prediluted on Ventana Ultra autostainer and INI1 (BD Biosciences, 612110)) 1:100 
using BondMax automated stainer. Anti-mouse or anti-rabbit secondary antibodies 
were used as appropriate.   
 
Immunocytochemistry was carried out on cells plated on poly-L-Lysine (Sigma) 
coated glass coverslips. The cells were washed briefly in PBS and then fixed in 4% 
paraformaldehyde solution for 15 min. Blocking and staining were carried out 
according to standard protocols. Antibodies: anti-transthyretin (1:500, Abcam), anti-
cleaved caspase 3 (1:500, Abcam) in 200 μl of blocking buffer and incubated for 3 
hours at room temperature. Secondary antibodies applied to the cells: donkey 
polyclonal anti-rabbit IgG-546 (1:500, ThermoFisher) or donkey polyclonal anti-
sheep IgG-594(1:250, Abcam) in 200 μl blocking buffer and incubated in the dark for 
1 hour at room temperature.  
 
For the EdU staining, Click-iT™ EdU Alexa Fluor™ Imaging Kit (ThermoFisher) was 
used. Cells were pre-treated with 10 µM of EdU for 3 hours at 37ºC before fixation. 
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After washing with PBS, cells were permeabilized with 0.1% Triton X-100 (Sigma) for 
20 min at room temperature. The Click-iT reaction cocktail was freshly prepared 
according to the instruction. Cells were incubated in this reaction cocktail for 30 min 
in the dark. After 3 washes (5 min each) in PBS, stained cells were mounted with 
Mounting Medium with DAPI (Vector Labs) on a glass microscope slide. Cells were 
viewed by Zeiss 710 Confocal Microscope.  
For quantification, 5 and 3 high power fields (representing a 400-fold magnification) 
were captured for each sample in human and mouse tumours respectively. Positive 
cells and total number of cells were counted by a researcher blinded to the 
experimental conditions of each slide. 
 
Fluorescent in-situ hybridisation (FISH) 
Unstained microtome sections of the FFPE tumour samples were analysed for C-
MYC and MYCN amplification by FISH. The procedure was carried out at Camelia 
Botnar Laboratory, Great Ormond Street Hospital. FFPE sections of 4m thickness 
on glass slides were dried and de-waxed by heating to 60°C in a dry oven, then 
washed in Xylene.  The xylene was removed by passing the slides through a series 
of ethanol washes. The slides were then placed in a saline sodium citrate (SSC 2X) 
solution at 70°C for one hour. After washing in distilled water the slides were then 
digested using a 4mg Pepsin solution in 0.2N hydrochloric acid solution at 37°C for 
20 minutes. The slides were then washed in distilled water and dehydrated by 
passing through a series of alcohol washes. FISH probe sets for MYC/CEP8 and 
MYC/CEP8/IGH (Abbott, USA) and MYCN/AFF3 (Leica, Germany) were prepared 
and hybridised according to the manufacturers’ instructions. Cell images were 
captured using Olympus BX61 (Olympus, Japan) and Zeiss Axioskop Imager 1 
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(Zeiss, Germany) microscopes; image analysis was performed using Cytovision 
(Leica, UK), Isis (Metasystems, Germany) and SmartCapture (Digital Scientific, UK) 
software. For analysis, a target number of 100 representative informative cells were 
examined from each hybridisation, with 50 cells being scored independently by two 
analysts. 
 
Gene expression profiling and pathway analysis 
Gene expression data measured on the Affymetrix Human Exon 1.0 ST array 
platform were obtained from Gene Expression Omnibus (GEO, accession 
GSE60892) for 40 patient tumour samples [4]. Six probes targeted c-MYC, five of 
which were positively correlated, with all pairwise Pearson correlation coefficients (r) 
greater than 0.5: 3115514, 3115515, 3115522, 3115523 and 3115524. To identify 
genes that correlated with c-MYC expression, Pearson correlation was performed on 
all probes against each of these five probes. We identified 1652 probes showing an 
absolute r ≥ 0.5 and p-value < 0.01 with at least one of the five c-MYC probes. The 
normalized expression values were standardised across each of these probes by 
subtracting the median value and dividing by the interquartile range. We then 
computed the mean standardised value of each of the genes represented across the 
1652 probe list. Comparing each of these aggregated genes against c-MYC, we 
retained 356 genes with absolute r ≥ 0.5 and p-value < 0.01 (Supplementary Material 
Genelists). A similar analysis was performed on the RNASeq dataset of 3 murine 
CPTs, to find genes correlating with c-MYC at the expression level, and 2290 genes 
were retained, with an absolute Pearson coefficient r ≥ 0.5 and p-value < 0.05.  
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The differential expression analysis between 3 murine control and 3 CPT samples 
was performed on edgeR [51], after TMM normalization, with a GLM model. 
Minimum log-fold change and FDR cut-off were set at 1 and 0.05, respectively.  
 
Adult human and murine CP transcriptomic profiles were obtained from a total of 18 
samples (9 human and 9 murine) to carry out a quantitative inter-species comparison 
at the gene expression level. The analysis was performed in R (version 3.4.3). The 
datasets are publicly accessible from GEO GSE82308 (6 murine samples), 
GSE23714 (3 murine samples), GSE68015 (3 human samples) and GSE110226 (6 
human samples). To perform the comparative analysis with data obtained from those 
different experiments and platforms, expression values were normalized with the 
YuGene package, which uses a cumulative proportion transform [52]. Only the 
shared genes between the two murine datasets (n=10300) and the shared genes 
between the two human datasets (n=14320) were used for further analysis. 
Orthologous genes were assessed via Ensembl BiomaRt [53] and the corresponding 
Bioconductor package in R.  
Hierarchical clustering was performed on genes using the Euclidean distance metric 
and Ward’s method. Pathway analysis of the genes was performed using Ingenuity® 
Pathway Analysis (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis).  
 
Soft agar assay 
Cells (7500 per well) were mixed with 0.3% noble agarose in complete growth 
medium as described above, plated on top of a solid field layer of 0.6% noble 
agarose in complete growth medium, in a 6-well plate. Cells were fed twice a week 
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with growth medium. After 4 weeks, the colonies were fixed and dyed with Cristal 
Violet (0.005% in 4% formaldehyde, Sigma), washed with PBS, and imaged. 
Colonies in the whole plate were then counted and data was analysed by Graphpad 
Prism. 
 
CD3 depletion in vivo 
NestinCre;STOPFloxc-MYC transgenic mice at the age of 9 months were injected 
with either Hamster anti-mouse CD3 IgG F(ab’)2 clone 145-2C11 (BioXCell Cat no. 
BE0001-1FAB) or hamster IgG F[ab’]2 isotype control (Cat no. BE0091-FAB) 
intraperitoneally. Eight mice (all het) were injected with isotype control and 9 mice (2 
hom, 3 het) with anti-CD3 antibody at dose of 100 µg/day for 5 days a week, for a 
duration of 4 weeks. The mice were observed for adverse symptoms and culled at 
the end of 4 weeks, brains collected, formalin fixed and paraffin embedded.  
 
Fluorescence-activated cell sorting 
Sampling blood and spleen: Peripheral blood (~ 30 µl) was collected from tail tip 
incision prior to injection and post injection by placing the mouse in a strainer. The 
blood was collected in EDTA coated Eppendorf tubes, treated with lysis buffer and 
centrifuged and pellet resuspended in FACS buffer. Post injection spleen samples 
were collected after the mice were culled at the end of 4 weeks observation. The 
spleen samples were mashed against a cell strainer and washed to break the tissue 
and collect the spleen cells. Further treatment with lysis buffer and washes were 
performed before a pellet containing approximately 6 x 107 cells was resuspended 
for use. 
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Cells from processed blood and spleen were stained in FACS buffer (1:200 BSA - 
Sigma, A3912 - and 1:250 EDTA 0.5mM – Ambion, AM9262 - in PBS). Cells were 
first treated with Anti-CD16/CD32 FcR blocker (eBiosciences, 140161-82) for 15min 
at 4°C. Antibodies were directly added to blocking solution and incubated for a 
further 30min at 4°C. Cells were then washed with FACS buffer and centrifuged 
(1500rpm, 5min). The cells were re-suspended in fixable fluorescent viability dye 
diluted in PBS and incubated for 20min at 4°C. The cells were then blocked with 4% 
PFA (1:1 in FACS buffer) for 15min. For intracellular staining, the cells were stained 
with antibodies diluted in 70% methanol for 20min at RT. The fixed cells were stored 
in FACS buffer at 4°C. FACS sample were run on an LSR II and were analysed 
using Flowjo version 10. Following removal of doublets and of dead cells, the gating 
for markers of interest was done using unstained samples and fluorescent minus one 
samples (FMOs) as controls. The following  fluorochromes were used - CD3-FITC, 
Fox-P3-PE, CD4-Pacific Blue, CD8-Pe-Cy7, CD45 and F4/80-APC 
 
Tumour area assessment 
CP and CPT area quantification was carried out on serial sections encompassing the 
entire CP/tumour with the Definiens Tissue Studio Software. A strategy composed of 
two steps, tissue detection and ROI detection, was set up to train the software to 
carry out automatic analysis of all the scanned H&E tissues. A rough tissue detection 
was first carried out to differentiate tissue from the glass slide, using the threshold 
pre-defined by the software. Composer initialisation allowed for the selection of 
subsets (tissue regions selected as examples), necessary for a more detailed 
definition of tissue versus glass slide. In Composer training, the subsets were 
segmented (threshold = 6), and tissue areas were selected versus glass slide areas 
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to teach the software. If the learning was adequate it was applied to the whole slide. 
Under ROI correction, CP and CPT area could be precisely selected. This step was 
manually carried out for each slide by two researchers blinded to the experimental 
conditions of each slide. 
 
Statistical analysis  
All quantitative experiments were performed at least in triplicates. A minimum of five 
high power fields were examined for each sample for each group in human tumours 
and a minimum of three high power fields in mouse samples, depending on the size 
of the tumour. Mean values are presented with error bars corresponding to ± SEM. 
Statistical analysis was performed by using GraphPad PRISM version 7.04 statistical 
analysis software. Significance is indicated as ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05.  
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Figure Legends 
Figure 1: CPT develop at high penetrance in NestinCre;STOPFloxc-MYC mice. 
 (A) Schematic of generation of double transgenic NestinCre;STOPfloxc-MYC mice. 
(B) CPT arising in a double transgenic mouse, with a tumour seen within the lateral 
ventricle (left) as compared to normal choroid plexus in the fourth ventricle (centre). 
(C) A large proportion (84.2%) of compound mice developed CPT (pie graph on the 
left); the majority of them (81.3%) were CPP, whist the rest (18.8%) were ACPP, 
(graph on the right). (D) GFP immunohistochemistry showing strong and even 
expression in the CPT as compared to control CP (inset). (E-H) H&E of CPT. CPP 
shows mild stratification of cells albeit with largely preserved papillary architecture 
and with mild cellular and nuclear pleomorphism (E, low magnification; G, high 
magnification) while ACPP showed moderate cellular and nuclear pleomorphism with 
more blunting of papillary architecture (F, low magnification and H, high 
magnification). In addition ACPPs showed significantly higher Ki-67 labelling as 
compared to CPPs (I, CPP; J, ACPP). K, Ki67 quantification (Bar graph representing 
average cells/HPF as mean ± SEM, n =3 in each cohort, * P<0.05).  Scale bar = 1 
mm (B), 250 m (D, E,F) and 125 m (G,H,I,J). 
Abbreviations: CP – choroid plexus; CPT-choroid plexus tumour; ACPP – atypical 
choroid plexus tumour; CPP – choroid plexus papilloma; NSPCs – neural stem 
progenitor cells; H&E – haematoxylin and eosin; GFP – Green Fluorescent Protein, 
indicative of c-MYC expression. 
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Figure 2: Increased proliferation and decreased apoptosis in CP cells 
overexpressing c-MYC.  
(A,B) Slightly enlarged CP was observed in NestinCre;STOPfloxc-MYC mice at P7 
as compared to controls. No histological atypia was noted. (C-F) Patchy hyperplasia 
with mild nuclear atypia was seen in NestinCre;STOPfloxc-MYC mice at P15 in 
comparison to controls. The hyperplastic areas showed GFP positivity in 
NestinCre;STOPfloxc-MYC mice, in keeping with activation of c-MYC construct. 
(G,H) At 3 months, widespread CP hyperplasia with mild nuclear atypia was 
observed in c-MYC overexpressing mice. (I-K) A trend toward increased proliferation 
was observed in the CP of NestinCre;STOPfloxc-MYC mice at E12.5, E16.5, P7 and 
P15, a finding which reached statistical significance from 3 months onwards (n = 6 in 
each cohort for 3 months and 6 months; n = 4 in each cohort for 9 months).  (L) 
Immunolabelling for transthyretin (TTR) confirmed the epithelial nature of the 
majority of the cultured cells. (M) GFP expression upon transduction with adeno-Cre 
(A-Cre) confirmed construct activation.  (N-P) Increased proliferation on Edu 
immunoassay and (Q-S) decreased apoptosis on cCasp3 immunoassay upon c-
MYC overexpression by A-Cre induced construct activation (cMYCOverCP) as 
compared to control CP cells. (T) Soft agar colony formation assay demonstrating 
cMYCoverCP cultures forming colonies as compared to control CP. A negative (no 
cells) and positive control (DAOY, medulloblastoma cell line) are included on the left; 
bottom panel shows high magnification images. (T) Quantification of the finding (n = 
3). 
K,M,P,S,U– Bar graph representing Mean ± SEM; * P<0.05; ** P<0.01; *** P<0.001. 
Scale bar is 125 m (L,N,O,Q,R).  
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Figure 3: c-MYC is expressed in a proportion of human CPTs.  
(A) Unsupervised hierarchical clustering analysis of 356 genes, the expression of 
which significantly correlated with c-MYC expression in 40 CPTs from Merino et al. 
dataset, showing clustering of CPTs based on c-MYC expression. The heat map 
colour for each tumour is defined by the Pearson correlation coefficient between the 
log-ratio expression profiles of genes. (B-G) Representative histology of the analysis 
of an independent (Brain UK) cohort of human CPT: papilloma, WHO grade I (B, 
CPP), atypical papilloma WHO grade II (C, ACPP) and carcinoma, WHO grade III 
(D, CPC). (E-F) c-MYC immunohistochemistry showing mostly diffuse expression (E) 
and in some cases focal expression (F). Nuclear expression of c-MYC in more than 
10% was considered as positive. (G) Graphical representation of cases positive for 
c-MYC, overall and among different histological subtypes.  18/42 (43%) of all cases 
were c-MYC positive; 4/6 (67%) CPC, 6/12 (50%) ACPP and 8/24 (33%) CPP were 
c-MYC positive. Scale bar = 125 m (B,C,D,E,F). 
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Figure 4: Deregulation of inflammatory pathways in NestinCre;STOPfloxc-MYC 
CPT. 
(A) Normalized c-MYC expression values (CPM) of 3 murine control and 3 CPT 
samples. Median and interquartile range are depicted. (B) IPA analysis on 
differentially expressed genes (n=245) between murine CPT and control samples. 
Positive z-score is associated with enrichment in the CPT context. (C) Unsupervised 
hierarchical clustering analysis and relative expression of c-MYC-correlated genes in 
the murine context (n=2290), across control and CPT samples. (D) Unsupervised 
hierarchical clustering analysis and relative expression of murine orthologs of c-
MYC-correlated genes in the human context (n=356), across control and CPT 
samples.  
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Figure 5: Characterisation of the inflammation in c-MYC+ CPT and c-MYCOver 
CPT. 
 (A) An increased T-lymphocytic infiltrate on CD3 immunohistochemistry in c-MYC+ 
tumours in relation to c-MYC- is noted (quantification showed on bar graph on the 
right; Mean ± SEM; n = 4 in each cohort; * P<0.05). (B) Subtyping of T-lymphocytes 
showed predominant increase in CD4 subtype population (quantification showed on 
bar graph on the right; Mean ± SEM; n = 11 for c-MYC+ and n = 10 for c-MYC-; * 
P<0.05). (C) Pronounced macrophage infiltration was also observed among c-MYC+ 
on CD68 immunohistochemistry (quantification showed on bar graph on the right; 
Mean ± SEM; n = 4 in each cohort; * P<0.05).    
(D,E) Comparative analysis of the CPT (CPP) developing in the c-MYC 
overexpressing mouse model as compared to normal CP showed T-lymphocytic (D) 
and macrophagic (E) infiltration in the tumour parenchyma. Quantification is shown 
on bar graph on the right; (D) Mean ± SEM; n = 6 in CPT and n = 7 in control; *** 
P<0.001 and (E) Mean ± SEM; n = 7 in CPT and n = 3 in control; ** P<0.01. Scale 
bar = 125 m (A,B,C,D,E). 
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Figure 6: CD3 depletion in NestinCre; STOPFloxc-MYC mice reduces 
proliferation and bulk of CPT.  
(A) A significant reduction in tumour incidence was noted in the triple compound 
mutant (NestinCre; STOPFlox-c-MYC;NOD-SCID) as compared to double 
compound mutant (NestinCre; STOPFlox-c-MYC). NODSCID mouse group 
confirmed no tumour development without c-MYC overexpression in an 
immunocompromised background. (B,C) Tumour area reduction, as assessed by 
Definiens® image analysis software in the triple compound mutant (B, right) as 
compared to double compound mutant (B, left). Representative tumour histology (B, 
upper panel) and tumour area measured on Definiens (B, lower panel, no colour). 
(C) Quantification bar graph with mean area ± SEM; n = 6 for double transgenic and 
n = 5 for triple transgenic; * P<0.05. (D) Flow peaks showing reduction in CD3+ cells 
in blood following anti-CD3 injection (pre-treatment blue, post treatment red peaks). 
(E) Reduction in CD3+ population was noted post injection in the anti-CD3 treated 
group in comparison to pre injections. No significant changes where observed in the 
isotype treated group. Common Leukocyte Antigen - CD45+ CD3+ cells were 
selected; Circles = pre-injection levels, Squares = post injection levels after 4 weeks, 
each representing one mouse. Mean ± SEM represented; * P<0.05. (F) Similar 
results were observed in spleen where a significant reduction of CD3+ cells was 
noted in post injection anti-CD3 cohort in comparison to isotype control; Mean ± 
SEM represented; ** P<0.01. (G) H&E of CPT assessed by Definiens® image 
analysis software showed a reduced tumour area in the anti-CD3 injected cohort in 
comparison to isotype injected tumours. Representative tumour histology (G, upper 
panel) and tumour area measured on Definiens (G, lower panel, red) and 
quantification in (H) bar graph with mean area ± SEM; n = 9 for anti-CD3 treated and 
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n = 8 for isotype control; * P<0.05. (I,J) Reduced number of CD3+  cells (arrow head) 
was observed in anti-CD3 treated group (right panel) in comparison to isotype 
control (left panel). (J) Quantification bar graph of Ki67+ and CD3+ cells with mean 
cells/HPF ± SEM; n = 9 for anti-CD3 treated and n = 8 for isotype control ; * P<0.05; 
*** P<0.001. Scale bar = 400 (G top) 200 m (G bottom) and 50 m (I). 
 
 












Figure S1: Generation of a mouse line to overexpress c-MYC in a 
spatiotemporally regulated manner.  
(A) Schematic of the Gateway Entry system monosite insertion of the human c-MYC 
construct into the ubiquitously expressed ROSA26 locus to generate a Cre-
activatable c-MYC construct. (B) Genotyping of the chimeras (het) showing detection 
of eGFP reporter gene on PCR. Germline transmission and establishment of line 
STOPFlox-c-MYC was achieved. (C) Western blot showing expression of human c-
MYC in NSPCs isolated from the postnatal transgenic mouse SVZ upon A-Cre 
infection. (D) Immunofluorescence assay showing concomitant expression of GFP in 
these cultures. Scale bar =125 m in D    
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Figure S2: c-Myc expression pattern in the developing and adult mouse brain. 
Representative images from Allen Brain Atlas (http://www.brain-map.org/) showing in 
situ hybridisation (ISH) of c-Myc expression at E18.5 (A,B,C) and in the adult brain 
(D,E,F).  G) Scattered epithelial cells of the postnatal CP express CFP and TTF1 in 
Nestin-CFP mice. H) Normalized c-MYC expression values in adult human and adult 
murine CP samples (YuGene normalization; median and interquartile range 
depicted). I) Transcriptome-wide Spearman’s rank correlogram of adult human and 
adult murine samples. The size and the shade of the circles are proportional to the 
correlation coefficient. MO; Murine, HU; Human. J) Venn diagrams showing the 
number of shared (orthologous) genes between the two species. K) Top enriched 
canonical pathways in human vs. murine CP (IPA, QIAGEN Inc.). Scale bar = 2.5 
mm (A,D), 500 m (B,C, E) and 250 m (F and G). 
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Figure S3: Inflammatory pathways in c-Myc overexpressing CPT. 
(A) 11 of top 20 genes significantly correlated with c-MYC expression in CPT from 
Merino et al. data were inflammation related- mostly chemokines and their receptors; 
correlation coefficient (r) in relation to c-MYC expression on Y-axis. (B) Pathway 
analysis of all 356 MYC-correlated genes found in the human context using 
Ingenuity® Pathway Analysis returned an enrichment of several immune-related 
canonical pathways. Threshold set at –log (p value) of ≥3. (C and D) Representative 
immune related pathways from the above analysis are shown; (C) Toll-like receptor 
signalling pathway and (D) Interleukin-10 (IL-10) signalling pathway; with common 
elements in the pathway with list of 356 correlated genes in grey/pink.    
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Figure S4: Transcriptome analysis of murine CPT. 
(A) Unsupervised hierarchical clustering analysis and relative expression of genes 
associated with Ji’s signature (c-Myc targets) in murine control and CPT samples. 
(B) Expression levels of Tp53 are not reduced rather increased, albeit not 
significantly in CPT.  
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Figure S5: Inflammatory cells in c-MYC overexpressing human CPT. 
(A) CD8 (cytotoxic T-lymphocyte, a subtype of T-cells) immunohistochemistry shows 
no significant difference in infiltrate cell counts between c-MYC+ and c-MYC-
tumours; quantification shown in bar graph on right hand side; Mean ± SEM; n = 10 
for c-MYC+ and n = 9 for c-MYC- cohorts; ns – no statistical significance. (B) CD20 
(B-lymphocyte marker) immunohistochemistry shows no significant difference in 
infiltrate cell counts between c-MYC+ and c-MYC- tumours; quantification shown in 
bar graph on right; Mean ± SEM; n = 11 for c-MYC+ and n = 9 for c-MYC- cohorts; 
ns – no statistical significance. (C,D) CD3 and F4-80 immunohistochemistry in 
NestinCre;c-MycSTOPFlox mice at different ages revealed no statistically significant 
increase in the number of T-lymphocyte (C) or macrophage (D) in the CP as 
compared to wild-type mice until tumour development at 9 months of age. 
Quantification bar graph on right side of C & D, Mean ± SEM; n for CD3 and F4-80 
studies in time points P15 = 4, 3m = 3, 6m = 6, 9m = 4 for both mCP and mCPT 
cohorts; * P<0.05. Scale bar = 125 m (A,B,C,D). 
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Figure S6: Quantification of inflammatory cells in anti-CD3 treated 
experimental mice.  
(A-C) A significant reduction in CD4 but not CD8 subpopulation was noted in mouse 
blood following anti-CD3 treatment. Flow peaks showing a significant difference (red 
= post treatment, blue = pre-treatment) for CD4 (A) but not statistically significant 
difference for CD8 (B), which are quantified in the graph in (C) showing mean values 
± SEM, n = 5 for isotype and n = 4 for anti-CD3 treated cohort, * P<0.05. (D) 
Reduction in CD4+ FoxP3+ (regulatory T-cells) population among CD3 T-cell 
population was noted following anti-CD3 injection, graph showing mean values ± 
SEM, n = 5 for isotype and n = 4 for anti-CD3 treated cohort, * P<0.05. (E,F) Anti-
CD3 treatment had no effect on macrophage (F4-80) population as shown on flow 
peak (E) and graph in (F) showing mean values ± SEM, n = 5 for isotype and n = 4 
for anti-CD3 treated cohort, * P<0.05. A reduction in F4-80 population was noted in 
post injection isotype treated group. (G) Reduction of mainly CD4, but not CD8 
subpopulation is also seen in spleen; graph showing mean values ± SEM, n = 5 for 
isotype and n = 4 for anti-CD3 treated cohort, ** P<0.01.    
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Table S1: Characteristics of CPT developing in the transgenic mouse model.   
 
Each tumour was histologically classified according to stratification of cells, loss of 
papillary architecture/solid growth and cellular & nuclear pleomorphism (- mild, 
moderate or severe). For mitotic activity mild = <2/10 HPF; moderate = 2 to 
5/10HPF; severe = >5/10 HPF. Based on the WHO criteria the tumours were 
classified as either CPP (with mild features) or ACPP (with moderate features). None 
of the tumours fulfilled the criteria to be classified as CPC.  
Abbreviations: Het – heterozygous; Hom – heterozygous; Symp – symptomatic; 
End – end of experiment following 20, 5-6 or 9-12 months of observation (as 
applicable); F – female; M – male; FV – fourth ventricle; LV – lateral ventricle; CPP – 
choroid plexus papilloma; ACPP – atypical choroid plexus papilloma; Mod – 
moderate; Sev – severe.   
* All mice are of genotype RosaMyc;c-MycSTOPFlox 
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Table S2: Patient demographics and tumour characteristics.  
Paediatric and adult patients were included and the tumours samples were of all 
three histological grades (CPP, ACPP and CPC).  
Abbreviations: F – female; M – male; FV – fourth ventricle; LV – lateral ventricle; 
TV – third ventricle; met – metastasis; CPP – choroid plexus papilloma; ACPP – 
atypical choroid plexus papilloma; IHC – immunohistochemistry.  
For recurrence, Y = yes; for c-MYC expression, F = focal (10-50%); D = diffuse 
(>50%)  
  * & ** are tumour tissue from same respective patients 
*** is an autopsy case 
 
